Evan J. McGillin

Associate

Evan J. McGillin advises clients on corporate matters with a focus on venture and growth capital, mergers and acquisitions (M&A), private equity transactions, and corporate governance. As a member of the firm’s emerging companies and venture capital practice, Evan represents established and emerging growth companies and the investors that finance them in a variety of industries including technology, fintech, advanced air mobility (including electric vertical takeoff and landing aircraft), digital health, and life sciences.

Evan regularly represents emerging growth companies throughout their entire life cycle, including formation, equity and debt financings, restructurings, M&A, and other strategic transactions. Additionally, Evan advises founders, senior management, and boards of directors on corporate governance, securities law compliance, equity and incentive structures, commercial agreements, and intellectual property matters.

Evan also represents angel, private equity, venture capital, strategic, and sovereign wealth fund investors in connection with financing transactions and M&A.

Show More

Financings

  • Represented Cambridge Mobile Telematics, the world’s largest telematics and AI company for safer mobility, in a $350 million strategic investment led by TPG and Allianz X, with participation from State Farm
  • Represented a gene therapy CDMO in multiple convertible debt and equity financings, raising more than $240 million in the aggregate
  • Represented Slide, an AI and insurtech startup, in its $100 million Series A financing
  • Represented a content management and digital experience software company in its $80 million Series C financing
  • Represented Bridge to Life, a market leader in organ preservation solutions and perfusion technologies, in its $110 million Series C and debt financing
  • Represented Alacriti, an innovative payments technology infrastructure provider, in its $55 million Series A equity financing led by Sageview Capital[
  • Represented Particle Health Inc. in its $12 million Series A financing led by Menlo Ventures
  • Represented a provider of a first-in-class epilepsy treatment in its $12 million convertible note financing
  • Represented a medical device manufacturer in its recapitalization and $15 million Series B financing
  • Represented the lead investors in a biopharmaceutical company’s $45 million Series C financing
  • Represented a leading provider of loss-control software for property and casualty insurers in its Series A-1 financing
  • Represented a US professional sports league in various equity and convertible debt financings
  • Represented a high-performance computing startup in its spinout from a Fortune 100 technology company and subsequent debt and equity financings, raising more than $50 million
  • Represented Chorus Healthcare, a precision pharmacy and clinical services organization focused on improving safety, outcomes, and efficiency in medication management for older adults and vulnerable populations, in its $6.6 million seed financing

Strategic Mergers & Acquisitions

  • Represented Red River, a technology transformation company specializing in AI-driven cybersecurity and information technology modernization solutions for government and enterprise customers, in its acquisition of Invictus International Consulting
  • Represented Engage Therapeutics Inc. in its sale to UCB (Euronext Brussels: UCB) for $125 million in upfront cash and up to $145 million in further potential milestone payments related to the clinical development, submission, and launch of Staccato® Alprazolam
  • Represented Amneal Pharmaceuticals Inc. (NYSE: AMRX) in its acquisition of a 65.1% majority interest in federal healthcare company AvKARE and its related affiliate doing business as R&S Northeast, a transaction valued at $340 million
  • Represented Humanwell Healthcare Group and PuraCap Pharmaceutical LLC in their acquisition of Epic Pharma of Laurelton, New York for $550 million
  • Represented Quantum Global Technologies LLC in its sale to Ultra Clean Holdings, Inc. (NASDAQ: UCTT) for approximately $342 million
  • Represented Marketeching Solutions, a leading research and social listening company, in its sale to W2O Group and its private equity sponsor Mountaingate Capital

 

Results may vary depending on your particular facts and legal circumstances.

  • Temple University Beasley School of Law, 2016, J.D., cum laude
  • Georgetown University, 2011, B.A.
  • New Jersey
  • Pennsylvania

Berkeley Law and the National Venture Capital Association's VC University Online, February 2021 Cohort

Member, Temple Law Review

No aspect of this advertisement has been approved by the Supreme Court of New Jersey. A description of the selection methodology for the above awards can be found here.